422270-30-2

Basic information

• Product Name: Piperazine, 1-(chloroacetyl)-4-[(4-fluorophenyl)methyl]-2-methyl-, (2R)-
• CAS NO: 422270-30-2
• Molecular Formula: C14H18ClFN2O
• Molecular Weight: 284.761
• Mol File: 422270-30-2.mol

Chemical Properties

• CAS DataBase Reference: Piperazine, 1-(chloroacetyl)-4-[(4-fluorophenyl)methyl]-2-methyl-, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 1-(chloroacetyl)-4-[(4-fluorophenyl)methyl]-2-methyl-, (2R)-(422270-30-2)
• EPA Substance Registry System: Piperazine, 1-(chloroacetyl)-4-[(4-fluorophenyl)methyl]-2-methyl-, (2R)-(422270-30-2)

Safety Data

• Hazardous Substances Data: 422270-30-2(Hazardous Substances Data)

Upstream product

• 352-11-4 1-chloromethyl-4-fluorobenzene 
• 75336-86-6 (2R)-methylpiperazine 
• 422270-29-9 (R)-1-(4-fluorobenzyl)-3-methylpiperazine 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 871324-85-5 2-{2-[(R)-4-(4-Fluoro-benzyl)-2-methyl-piperazin-1-yl]-2-oxo-ethyl}-isoindole-1,3-dione 
• 422270-31-3 2-(4-chloro-2-nitro-phenoxy)-1-[4-(4-fluoro-benzyl)-(2R)-2-methyl-piperazin-1-yl]-ethanone 
• 217645-70-0 1-(5-chloro-2-{2-[(2R)-4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy}phenyl)urea 
• 871324-84-4 2-(4-Chloro-2-nitro-phenylamino)-1-[(R)-4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-ethanone 
• 871324-86-6 2-(2-Amino-4-chloro-phenylamino)-1-[(R)-4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-ethanone 
• 871324-83-3 2-Amino-1-[(R)-4-(4-fluoro-benzyl)-2-methyl-piperazin-1-yl]-ethanone 

Relevant articles and documents

Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists

Design and synthesis of a series of 3-amino-4-(2-(2-(4-benzylpiperazin-1-yl)-2-oxoethoxy)phenylamino)cyclobutenedione derivatives as novel CCR1 antagonists are described. Structure-activity relationship studies led to the identification of compound 22, which demonstrated potent binding activity, functional antagonism of CCR1 as well as good species cross-reactivity. In addition, compound 22 also showed desirable pharmacokinetic profiles and was selected for in vivo studies in the mouse collagen-induced arthritis model.

Methods of using piperazine derivatives

The present invention relates to compounds of the formula I and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.